Stockwinners Market Radar for August 31, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:04 EDT Unity director sells $2.58M in common stock - In a regulatory filing, Unity disclosed that its director Shlomo Dovrat sold 68.5K shares of common stock on August 30th in a total transaction size of $2.58M.

19:04 EDT Sony says PlayStation Portal to launch November 15 - Sony said the PlayStation Portal remote player will launch November 15. Reference Link

18:22 EDT Globalstar director buys $4.76M in common stock - In a regulatory filing, Globalstar disclosed that its director James Monroe bought 4.2M shares of common stock on August 29th in a total transaction size of $4.76M.

17:37 EDT Datadog Director Matthew Jacobson sells $2.1M in shares - Datadog Director Jacobson disclosed the sale of 22,391 shares of company stock on August 29 at $93.80 per share on August 29, for a total transaction amount of $2,100,253.

17:22 EDT BAE Systems awarded $100.92M Defense Logistics Agency contract modification - BAE Systems has been awarded a maximum $100.92M modification against a 10-year subsumable contract, with two one-year ordering periods for ALR-56M radar warning receiver shipsets. This is a firm-fixed-price requirements contract. Location of performance is New York, with a March 31, 2024, ordering period end date. Using military service is Air Force. Type of appropriation is fiscal 2023 through 2024 defense working capital funds. The contracting activity is the Defense Logistics Agency Land and Maritime.

17:21 EDT Boeing awarded $173.61M Navy delivery order - Boeing was awarded $173.61M for a delivery order under a previously awarded basic ordering agreement for the repair of landing gear used on the F/A-18 E/F aircraft. Work is expected to be completed by August 2026. Working capital funds in the amount of $85.07M will be obligated at time of award and funds will not expire at the end of the current fiscal year. One company was solicited for this sole-source requirement pursuant to the authority set forth in 10 U.S. Code 2304, with one offer received. Naval Supply Systems Command Weapon Systems Support is the contracting activity.

17:18 EDT BAE Systems awarded $274.1M Army contract - BAE Systems was awarded a $274.1M hybrid contract to produce M2A4 and M7A4 vehicles from various inducted legacy source variants. Bids were solicited via the internet with one received. Work will be performed in York, Pennsylvania, with an estimated completion date of January 31, 2026. FY23 procurement of weapons and tracked combat vehicles, Army funds in the amount of $274.1M were obligated at the time of the award. Army Contracting Command is the contracting activity.

17:15 EDT Leidos awarded $7.9B Army contract - Leidos was awarded a $7.9B firm-fixed-price contract for hardware systems, system management solutions, components, customizable sustainment strategies, non-personal services and continuous technology upgrades. Bids were solicited via the internet with three received. Work locations and funding will be determined with each order, with an estimated completion date of Aug. 30, 2033. Army Contracting Command is the contracting activity.

17:01 EDT Oceaneering awarded international contracts with combined value of over $100M - Oceaneering "announces that its Offshore Projects Group segment has been awarded two international contracts, with combined total value in excess of $100 million."

16:48 EDT SentinelOne up 9% at $18.20 after Q2 earnings beat, above-consensus guidance

16:45 EDT Eos Energy jumps 44% to $4.66 after announcing $500M 'Project AMAZE'

16:36 EDT Centogene receives noncompliance notification from Nasdaq - Centogene announced that it has received a written notification from Nasdaq, indicating that the company is not in compliance with the minimum Market Value of Publicly Held Shares, or MVPHS, set forth in the Nasdaq Rules for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5450(b)(3)(C) requires companies to maintain a minimum MVPHS of $15M, and Listing Rule 5810(c)(3)(D) provides that a failure to meet the MVPHS requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the MVPHS of the company for the 30 consecutive business days from July 19 to August 29, the company no longer meets the MVPHS minimum requirement. This notification does not impact the listing and trading of the company's securities at this time.

16:26 EDT Workday co-CEO bought $2.09M in common stock - In a regulatory filing, Workday disclosed that its co-CEO Carl Eschenbach bought 8,676 shares of common stock on August 29th in a total transaction size of $2.09M.

16:19 EDT Ross Stores chairman Orban to step down - Ross Stores announced that its Board of Directors has approved the following changes to its Board leadership and composition effective September 1, 2023: George P. Orban will step down as Chairman of the Board while continuing to serve as an independent Director; Michael Balmuth, currently Strategic Advisor to the Company, will return to the Executive Chairman of the Board role; K. Gunnar Bjorklund will become Lead Independent Director. In commenting, Chairman George Orban said, "While personal reasons were the catalyst for my stepping down as Chairman, I plan to stay actively involved in the business as an independent Director. Also, on behalf of the entire Board, we are delighted that Michael Balmuth has agreed to become Executive Chairman of the Board. He previously served as Chairman of the Board from 2014 to 2021, including Executive Chairman to 2019 before transitioning into an advisory role. We also thank Gunnar Bjorklund for assuming the Lead Independent Director position."

16:17 EDT ClearSign provides operational update for Q2 2023 - ClearSign provided an update on operations for Q2 2023. "Our order flow increased in Q2, both in process burners and our boiler burner line," said Jim Deller, CEO. "The execution of these initial sales, for both boiler burners and process burners, will set the stage for our future growth...We are very encouraged by the engagement we are receiving in the industry regarding our technologies and we believe that our recently announced Phase 2 government grant award through the Small Business Innovative Research program with the Department of Energy, which provides direct support for the engineering and commercialization of our 100% hydrogen burner products, will further enhance our visibility in the industry". Q2 operational highlights include: completed successful Phase 1 testing of ultra-low NOx 100% hydrogen burner, awarded Phase 2 SBIR grant for $1.65M; received engineering order and follow on order for two multi burner heaters from a California refinery; entered the Texas Gulf Coast market with burner sale to global chemical company scheduled to be installed in Q3; recognized approximately $150K in revenue during the three months ended June 30, 2023, as compared to zero revenue for the same period of 2022. Cash, cash equivalents and short-term investments were approximately $8.5M as of June 30, 2023. There were 38,562,086 shares of the Company's common stock issued and outstanding as of June 30, 2023.

16:16 EDT Nutanix board authorizes repurchase of up to $350M of class A stock - Nutanix announced that its Board of Directors has authorized the repurchase of up to $350 million of its Class A common stock. "We remain focused on investing in our business to support profitable growth and on delivering strong returns for shareholders. This share repurchase program is consistent with these objectives and a reflection of the confidence we have in our long-term market opportunity and financial outlook," said Nutanix CFO, Rukmini Sivaraman.

16:11 EDT MongoDB reports over 45,000 customers as of July 31

16:10 EDT Methode Electronics CEO Donald Duda to retire - Methode Electronics announced that Donald Duda, president and CEO, will retire from Methode. He will continue to lead the company until a successor has been named and will work with the new CEO through a transition period, which is expected to conclude during fiscal 2025. Methode's board of directors, with the assistance of executive search firm Spencer Stuart, has already begun an external search process to identify Duda's successor. Duda has agreed to offer his resignation as a director as of the appointment of his successor.

16:08 EDT Avista announces new electric and natural gas rates in Idaho - Avista received approval from the Idaho Public Utilities Commission, PUC or Commission, of the multiparty settlement agreement that was filed on June 14 , concluding the Company's electric and natural gas general rate cases. The approved rates are designed to increase annual base electric revenues by $22.1Mor 8.0%, effective Sept. 1, and by $4.3M or 1.4%, effective Sept. 1, 2024. For natural gas, the approved rates are designed to increase annual base natural gas revenues by $1.3M or 2.7%, effective Sept. 1 and by $0.003Mor 0.01%, effective Sept. 1, 2024. The settlement capital structure includes a 9.4% return on equity ROE with a common equity ratio of 50% and a rate of return ROR on rate base of 7.19%. "The Commission's decision provides new electric and natural gas rates in Idaho that are reasonable for our customers, the Company and our shareholders," said Dennis Vermillion, Avista president and CEO. "This outcome provides us the opportunity to earn a fair return in Idaho and supports Avista's efforts to make key capital investments so we can continue to provide the reliable energy our customers expect."

16:04 EDT Eos Energy announces $500M program for long-duration energy storage demand - Eos Energy Enterprises announced Project AMAZE ,American Made Zinc Energy, a $500M planned expansion and a significant milestone to build 8 GWh of clean energy storage production capacity. Project AMAZE supports Eos' strategy to address increased long-duration energy storage demand driven by the Inflation Reduction Act, IRA implementation, using its Eos Z3 energy storage system. The project secured an up to $398.6M conditional commitment for a loan guarantee from the DOE LPO, the result of a rigorous and thorough due diligence process by the DOE that, if the loan is finalized, would fund 80% of Eos' planned expansion. In 2018, Eos brought its production and supply chain back to the United States from China, and the expanded facility would further build on Eos' investment in American manufacturing with the increased production of its zinc-based energy storage systems...The Eos Z3 battery contains predominately American components and is specifically designed for mass production and meeting low-cost, long-duration, grid-scale stationary energy storage needs. .. "We are excited to formally announce Project AMAZE. The IRA implementation requires us to move with speed and urgency if the energy industry is going to meet the demand for long-duration energy storage," said Joe Mastrangelo, CEO of Eos Energy Enterprises.

15:23 EDT Procter & Gamble COO Jejurikar sells 11,522 common shares - In a regulatory filing, Procter & Gamble COO Shailesh Jejurikar disclosed the sale of 11,522 common shares of the company on August 30 at a price of $154.1335 per share.

14:47 EDT Vahanna Tech Edge Acquisition I Corp trading resumes

14:42 EDT Vahanna Tech Edge Acquisition I Corp trading halted, volatility trading pause

14:31 EDT FTC settles challenge to ICE acquisition of Black Knight - The Federal Trade Commission today approved a proposed consent order to resolve antitrust concerns surrounding Intercontinental Exchange's (ICE) proposed acquisition of Black Knight (BKI). Under the terms of the proposed order, Black Knight's Optimal Blue business and Empower business, along with certain related products, will be divested to Constellation Web Solutions. ICE and Black Knight are required to maintain the viability of the businesses until they are successfully divested to Constellation, and to provide transition assistance to enable Constellation to operate the businesses along the same lines that Black Knight has operated them. The proposed consent order also requires ICE and Black Knight, for the next 10 years, to seek prior approval from the FTC before either reacquiring any divested asset or acquiring an interest in a loan origination system business. Reference Link

13:42 EDT Intel up 2% after CEO says Q3 tracking above guidance midpoint

13:38 EDT Sculptor founding partners request more information about $12.76 bid - The Founding Partners of Sculptor Capital Management (SCU), which include Daniel Och, Harold Kelly, Richard Lyon, James O'Connor and Zoltan Varga, commented on the recent disclosure that the Sculptor Special Committee of the Board of Directors has rejected a $12.76 per share offer by a consortium of well-known investors. The Special Committee has disclosed its continued support for an $11.15 per share offer from Rithm Capital Corp (RITM). The Founding Partners said: "We call upon Sculptor to release more information about the $12.76 bid from the 'Bidder J consortium.' We know that $12.76 is materially higher than the $11.15 Rithm bid, and it has been widely reported that the consortium includes Boaz Weinstein, Marc Lasry, Bill Ackman and Jeff Yass, some of the most acclaimed investors of the last 25 years. It seems evident that such a group could augment Sculptor's investment team while paying much more cash to the shareholders. Many shareholders and investors are eager to hear more about such a bid, and we urge the Board to do its fiduciary duty and waive the NDAs to maximize the bidding process and achieve the highest value for shareholders. The shareholders and investors who must consent to the Rithm bid are entitled to full disclosure about the available alternatives."

13:33 EDT Intel rallies 1% to $34.98 during conference presentation

13:12 EDT Digital Brands Group Inc trading halted, volatility trading pause

13:00 EDT ADiTx Therapeutics trading halted, volatility trading pause

12:35 EDT Mogo regains compliance with Nasdaq minimum bid price rule - Mogo has received formal notice from the Nasdaq Stock Market stating that the Company has regained compliance with the minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. The notice indicated that, as a result of the closing bid price of the Company's common share having been $1.00 per share or greater for at least ten consecutive business days, from August 14, 2023 through August 25, 2023, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and the matter has been closed.

12:00 EDT Chewy falls -11.2% - Chewy is down -11.2%, or -$3.06 to $24.27.

12:00 EDT Ciena rises 15.1% - Ciena is up 15.1%, or $6.50 to $49.66.

12:00 EDT Spire Global rises 723.0% - Spire Global is up 723.0%, or $4.08 to $4.65.

10:46 EDT eMagin stockholders approve acquisition by Samsung Display - eMagin stockholders voted to approve eMagin's pending acquisition by Samsung Display at eMagin's special meeting of stockholders. The final voting results on the proposals voted on at the special meeting will be set forth in a Form 8-K filed by eMagin with the U.S. Securities and Exchange Commission, after certification by eMagin's inspector of elections. The transaction is currently expected to close in the second half of 2023, subject to customary closing conditions, including the receipt of regulatory approvals. Upon completion of the transaction, eMagin common stock will no longer trade on the NYSE American, and eMagin will become a private company.

10:06 EDT Alkami partners with Atomic for direct deposit switching solution - Alkami Technology has partnered with Atomic to provide financial institutions with a direct deposit switching solution that allows account holders to seamlessly connect their payroll accounts to any financial institution. As part of the partnership, Atomic's direct deposit switch solution will be integrated into Alkami's Digital Banking Platform. This will make it easier for community and regional financial institutions to offer their account holders a quick and convenient way to set up and switch direct deposits, further helping financial institutions to grow direct deposits, account acquisition, and primary relationships. This enhancement eliminates paper processes, significantly decreases wait times often incurred with traditional methods, and reduces the cost of deposit acquisition.

10:03 EDT Tarsadia Investments urges Cue Health board to undertake strategic review - Tarsadia sent an open letter to the board of directors of Cue, which read in part, "Today, we are recommending the Board take the following immediate actions: Conduct a strategic review of management's standalone long-term business plan and the capital required to execute upon that plan. It is the Board's responsibility to address whether the execution risk and capital required to execute the current business plan will create more value than other strategic alternatives. In order to properly vet these paths, we believe the Board must form a special committee of independent directors and retain financial advisers to help in this review. Review the Company's flawed approach to capital allocation and realign its unsustainable cost structure. We believe Cue must achieve an additional $50 million in annualized cost savings to extend its liquidity runway into 2025. The Company's cost structure does not reflect the reality of a post-COVID revenue environment and Cue's valuable remaining cash resources must be focused on its core businesses. Cue should focus on supporting its diagnostic products and curtail its non-core businesses: Cue Lab and Cue Pharmacy. Additionally, Cue should focus its sales efforts on large-scale commercial deals that include up-front payments while eliminating the infrastructure and marketing spend supporting direct-to-consumer and small and medium sized customers that have historically generated limited revenues. Cue must appoint independent stockholder representatives to the Board who can contribute a sense of urgency and fresh perspective to Board deliberations. These independent stockholder representatives should be appointed to the special committee that will explore strategic alternatives. With these appointments, working together, the directors can exercise their duty to act as independent fiduciaries for stockholders, set the Company's strategy, determine its capital allocation approach and hold management accountable. Call for Action Members of the Board, Cue's trajectory is not sustainable and puts all stockholders at risk. We are strong believers in the technology that Cue has developed and have great respect for the critical role the Company played in providing testing during the pandemic. We believe that Cue's industry-leading technology has the potential to substantially improve the way we diagnose acute and chronic conditions. However, immediate action must be taken to preserve and grow this potential. As fiduciaries and representatives of stockholders, we hope that you will reflect on the destruction in stockholder value that has occurred under your stewardship and listen to the many stockholder voices, representing substantial stockholdings, calling for an urgent and immediate change of course. Concurrently, with this letter, our legal counsel is submitting to the Board a Section 220 demand request to inspect the Company's "Books and Records" to investigate potential breaches of fiduciary duty and/or other wrongdoing related to mismanagement and test the propriety of the Company's public disclosures."

10:00 EDT Marriott Vacations says cancelled Maui reservations through Sept. 10 after fires - Marriott Vacations Worldwide provided an update today on the anticipated business impact of the Maui wildfires on its operations and financial results. "The company operates four vacation ownership resorts and sales centers in West Maui representing more than 10% of its annual contract sales. In addition, its Aqua-Aston Hospitality property management business manages five properties in West Maui... Following the wildfire devastation in West Maui on August 8, the company enacted its disaster response protocols to reinstate power, internet and cell communication as quickly as possible. The inability to communicate at the onset with resort leadership, Owners, guests and associates proved challenging as the infrastructure around the town of Lahaina was impaired. With a large percentage of the company's nearly 1,700 associates on Maui sustaining significant damage to, or loss of, their homes and belongings, efforts have been focused on providing immediate relief while assessing the impacts and the long-term needs of its associates. The company is providing temporary housing, food, supplies, on-site counseling, and fiscal benefits like disaster pay. An existing non-profit Relief Fund affiliated with the company is also providing expedited relief grants while raising funds to aid those associates and their families who incur significant damage or displacement after a natural or civic disaster such as the wildfires in Maui. Physical damage to the company's resorts and sales centers is minimal, however, with continued recovery efforts ongoing in West Maui and the challenging environment visitors will face if traveling to the area, the company has cancelled all Owner and exchange reservations through at least September 10, 2023 and all transient rental and preview arrivals through at least the end of September. As a result, the company expects contract sales in the third quarter to be adversely impacted by approximately $25 to $30M. In addition, because of lower contract sales and impacts to the Company's other Vacation Ownership business lines, as well as impacts to its Exchange and Third-party Management segment, the Company currently expects the Maui wildfires to negatively impact its third quarter Net income attributable to common shareholders by $16 to $19M and its Adjusted EBITDA by $22 to $27M. While the company intends to pursue relief available through insurance options, it is too early to estimate any recovery. The impact of the Maui wildfires on fourth quarter operating results will depend on the timing of the re-opening of our resorts and the pace that travel returns to the island of Maui," the company stated.

10:00 EDT Chewy falls -13.1% - Chewy is down -13.1%, or -$3.58 to $23.75.

10:00 EDT Ciena rises 13.4% - Ciena is up 13.4%, or $5.78 to $48.94.

10:00 EDT Express rises 1801.5% - Express is up 1801.5%, or $9.01 to $9.51.

09:51 EDT Dream Chasers Capital offers to acquire Carver for $3.00 per share - On August 14, 2023, Dream Chasers Capital Group, one of Carver Federal Savings Bank's biggest shareholders of record with a 5.5% stake, has made a significant offer to buy 35% of the bank's shares for $3 a share, a premium above the current stock price. Dream Chasers, a New York City based minority-run Investment Fund, made the offer in a letter to Carver's Board of Directors dated August 14, 2023. Dream Chasers has been in active talks with the bank for months about acquiring a significant interest. By making this offer, the Investment Fund hopes to take control of the bank and replace the current management and board with an already assembled world-class team of minority executives who have a combined 40 years of experience as CEO or senior executives at some of the largest banks and financial service companies. Dream Chasers plans to recapitalize the bank and introduce a platform of value-added wealth building services to attract new depositors, thus leading to an increase in shareholder value. Communities of color lack basic structure, financial services offerings and products to build, maintain and pass on generational wealth. By taking control of Carver and implementing these wealth building services, the fund believes this will uplift and create substantial wealth in communities of color. Dream Chasers have dubbed this wealth building initiative-Project Uplift. Carver was founded 75 years ago by Black and Caribbean American business owners with a mission to create a bank where minority entrepreneurs could get easy access to capital when other banks would not lend to them. 75 years later, poor execution and mismanagement, have left the bank on shaky financial footing, losing deposits, overconcentrated in commercial real estate and unable to serve any of its constituents' well-shareholders, depositors, or the community. By going public with its $3 per share offer to take a controlling interest, Dream Chasers is seeking to rally support for Project Uplift-in whatever form that may come-from civil society builders, like-minded shareholders, activist of all stripes, financial executives, corporations, current Carver bank employees, social media influences, celebrities, professional athletes, entertainers, business titans and all constituents who have a vested interest in seeing communities of color build generational wealth.

09:47 EDT Chewy falls -10.8% - Chewy is down -10.8%, or -$2.96 to $24.37.

09:47 EDT KE Holdings rises 20.1% - KE Holdings is up 20.1%, or $3.14 to $18.80.

09:47 EDT Express rises 1702.0% - Express is up 1702.0%, or $8.51 to $9.01.

09:37 EDT Peak Bio uplists to OTCQB Market - Peak Bio announces its up-listing from the OTC Pink Market to the OTCQB Venture Market effective for trading August 31, 2023 at the open. Peak Bio will continue to trade under the ticker symbol "PKBO".

09:35 EDT SeqLL Inc trading resumes

09:31 EDT MGM Resorts, BetMGM launch responsible gaming campaign at NFL stadiums - MGM Resorts International and BetMGM announced they are launching a responsible gaming campaign at nine National Football League stadiums, promoting their responsible gaming program GameSense during the upcoming football season. With this development, MGM Resorts and BetMGM are among the first gaming operators to promote responsible gaming through marketing within League venues. Additionally, MGM Resorts and BetMGM are committing more than $1M annually to fund a variety of responsible gaming and problem gambling initiatives. This includes research, advocacy, prevention, marketing, and organizational support.

09:31 EDT iCoreConnect Inc trading halted, volatility trading pause

09:27 EDT 1847 Holdings announces restructuring of promissory notes - 1847 Holdings announced that it has successfully restructured all of its Promissory Notes, with two institutional investors, totaling approximately $1.75 million outstanding. Based on the agreements with the investors, the Promissory Notes are no longer convertible to equity, as long as they are repaid by the Company over a 12 month amortization schedule.

09:19 EDT Clayton, Dubilier & Rice completes acquisition of Focus Financial Partners - Focus Financial Partners, Clayton, Dubilier & Rice, and Stone Point Capital announced that they have completed the previously announced acquisition of Focus by funds affiliated with CD&R and Stone Point in an all-cash transaction for an enterprise value in excess of $7B. With the completion of the transaction, Focus's common stock has ceased trading and is no longer listed on NASDAQ.

09:17 EDT Utah Medical Products provides update on Filshie product liability lawsuits - As Utah Medical Products stockholders know, the following disclosure was included in the Company's 2022 SEC 10-K annual report, released in March 2023: "In late 2021, after the Filshie clip had been used in the U.S. for 25 years and implanted in millions of women, a clip migration lawsuit was filed in Texas. Subsequently, the same law firm solicited and recruited claimants in other states. As of the end of January 2023, there were a total of fourteen clip migration lawsuits initiated by the same law firm in twelve different states. UTMD has filed motions to dismiss in most of those lawsuits, one of which has been granted. A dismissal can be appealed, but as of yet hasn't been. Management expects others to be dismissed based on legal grounds such as lack of jurisdiction or U.S. FDA preemption." UTMD now provides an update on the status and progress of these lawsuits. There were 71 total claimants represented in the fourteen lawsuits referenced above. All of the lawsuits except one were filed in federal courts. The exception was a lawsuit with 50 claimants filed in Utah State court. The thirteen other lawsuits were comprised of a total 21 claimants. On August 29, the UT state court dismissed the UT complaint with prejudice. Three of the original thirteen federal lawsuits have also been dismissed to date. However, since the above disclosure, plaintiff law firm has continued to solicit for claimants through social media, and filed additional lawsuits with pleadings substantially the same in all. The court opinions supporting dismissal have been provided as supplemental authority to the other courts with open dismissal motions. Two additional federal lawsuits and one additional state lawsuit have been filed since the SEC 10-K disclosure. One of the additional federal lawsuits in New York has already been dismissed, for a total of five dismissals. The additional state lawsuit was filed in Connecticut, originally in April with 10 new claimants. The CT lawsuit has been twice updated adding new claimants, most recently this week. The CT lawsuit now has 43 new claimants. n summary, as of this date, seventeen lawsuits have been filed in fourteen states, with a total of 117 claimants. All except two lawsuits were filed in federal courts. The two state lawsuits were filed in UT and CT, the domiciles of UTMD and CooperSurgical, Inc, respectively. None of the lawsuits have gone to trial yet, and several have motions to dismiss still pending. As of this date, five lawsuits comprised of fifty-four claimants have been dismissed. There remain twelve lawsuits in eleven states comprised of sixty-three new claimants.

09:13 EDT Alpine 4 Holdings secures contracts totalling $9M with U.S. Department of State - Alpine 4 Holdings and its Subsidiary, Thermal Dynamics International announce the procurement of multiple contracts with the United States Department of State through several government contractors, collectively valued at $9 Million. Further, the Company's backlog has now swelled to over $19 Million and is expected to keep growing as the Government's fiscal year end approaches on September 30, 2023. These contracts signify a pivotal step forward in TDI's growing relationship with government agencies and underscore its commitment to implementing high-impact thermal solutions for the public sector.

09:12 EDT LQR House announces collaboration with OpenAI's ChatGPT - LQR House announces its collaboration with OpenAI's ChatGPT. This partnership marks a significant step forward in the realm of e-commerce and customer interaction. With the seamless integration of ChatGPT into the CWSpirits.com platform, LQR House strives to deliver an elevated shopping experience that is both personalized and informative, resulting in heightened awareness and enhanced conversion rates. LQR House's use of OpenAI's ChatGPT brings forth an innovative approach to customer interaction. The incorporation of artificial intelligence into CWSpirits.com provides customers with customized shopping recommendations and instant answers to product inquiries. Named LQR Genius, the AI-powered chatbot facilitates direct engagement, offering swift and precise responses that enhance product comprehension and refine the shopping journey.

09:08 EDT CareCloud to exhibit at Fall Revenue Cycle Management Conference - CareCloud announced its participation in the upcoming Healthcare Business Management Association 2023 Fall Revenue Cycle Management Conference. This milestone event, commemorating HBMA's 30th year anniversary, will be held Sept. 26-28, 2023, at the JW Marriott in Indianapolis, IN. Attendees will also be able to engage with CareCloud Force President Karl Johnson who will be in CareCloud's booth. CareCloud Force is a workforce extension service that helps healthcare organizations streamline their administrative tasks and scale their businesses. The company's team of experienced professionals can take on a variety of tasks, including revenue cycle management, robotic process automation, provider credentialing, patient collection services, authorization management, and out-of-network billing.

09:07 EDT LifeVantage adopts limited duration stockholder rights plan - LifeVantage Board of Directors has adopted a limited duration stockholder rights plan. The adoption of the Rights Plan is intended to protect the long-term interests of LifeVantage and all LifeVantage stockholders and enable them to realize the full potential value of their investment in the Company. The Rights Plan is designed to reduce the likelihood that any entity, person or group would gain control of, or significant influence over, LifeVantage through the open-market accumulation of the Company's shares without appropriately compensating all LifeVantage stockholders for control. The Rights Plan is not intended to prevent or interfere with any action with respect to LifeVantage that the Board determines to be in the best interests of the Company and its stockholders. Instead, it will position the Board to fulfill its fiduciary duties on behalf of all stockholders by ensuring that the Board has sufficient time to make informed judgments about any attempts to control or significantly influence LifeVantage. The Rights Plan will encourage anyone seeking to gain a significant interest in LifeVantage to negotiate directly with the Board prior to attempting to control or significantly influence the Company. The Board intends to submit the Rights Plan to stockholders for ratification at the Company's upcoming Annual Meeting of Stockholders and to terminate the Rights Plan if the proposal to ratify the Rights Plan is not approved at that meeting. If the Rights Plan is ratified at the Annual Meeting, it will expire no later than August 28, 2024, subject to the terms of the Rights Plan. The date of the upcoming Annual Meeting has not yet been announced. Further, the terms of the Rights Plan provide many recognized stockholder protections, including the following: The rights will be exercisable only if any entity, person or group acquires 12% or more of the Company's outstanding common stock in a transaction not approved by the Board; The Rights Plan has an exception for offers made for all shares of the Company that treat stockholders equally and recognize the full value of the Company, including a qualifying offer clause that provides stockholders the ability to call a special meeting for purposes of exempting a "qualifying offer," as described further in the Rights Plan; The Rights Plan does not contain any dead-hand, slow-hand, no-hand or similar features that would limit the ability of a future board of directors to redeem the rights; and The Rights Plan does not preclude the Board from considering an offer that recognizes the full value of the Company. Pursuant to the Rights Plan, LifeVantage will issue one right for each share of common stock outstanding as of the close of business on September 11, 2023. While the Rights Plan is effective immediately, the rights generally would become exercisable only if an entity, person or group acquires beneficial ownership of 12% or more of LifeVantage's outstanding common stock in a transaction not approved by the Board. In that situation, each holder of a right will have the right to purchase from the Company for $20.00, subject to certain potential adjustments, shares of LifeVantage's common stock having a market value of twice that amount. In addition, at any time after an entity, person or group acquires 12% or more of the Company's outstanding common stock, but less than 50% of the Company's outstanding common stock, the Board may exchange one share of the Company's common stock for each outstanding right.

09:07 EDT SunCar Technology announces services agreement with CMBC - SunCar Technology announced that it has renewed its annual destination pickup service agreement with China Minsheng Banking, CMBC. SunCar's destination pickup service that covers 79 airports and 330 high-speed rail stations in China.

09:04 EDT Fat Brands opens co-branded Great American Cookies, Marble Slab Creamery store - FAT Brands announces the opening of a co-branded Great American Cookies and Marble Slab Creamery location in Happy Valley, Oregon. Situated in Clackamas County, the new store marks the first Pacific Northwest location for both brands.

08:57 EDT Academy Sports jumps 12% to $55.92 after Q2 earnings beat, FY23 guidance raise

08:51 EDT Polaris Marine selects Forza X1 to electrify two pontoon boats - Forza X1 announced today that Polaris Marine selected Forza X1 to electrify two pontoon boats as demonstration units for Bennington and Godfrey Pontoon. Over the last several weeks, Polaris Marine revealed they showcased several high-horsepower EV concept vessels at their annual dealer meetings in Syracuse, Indiana. Bennington and Godfrey Pontoon utilized the Forza X1's outboard motor to test and demonstrate the potential for the future development of watercraft optimized for electric propulsion. Forza's motor powered two concept vessels, including the 26-foot, 6-inch 2024 Bennington L-Series Bowrider and the 23-foot, 11-inch 2023 Godfrey Monaco 235 platforms.

08:42 EDT FOXO Technologies announces NYSE American acceptance of compliance plan - FOXO Technologies received a late from NYSE American stating that NYSE American reviewed and accepted the plan of compliance submitted by the Company in response to NYSE American's June 12 notice informing the Company that it was not in compliance with the continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide. The Letter provides an extension for compliance with Section 1003(a)(i) of the Company Guide until December 12, 2024. NYSE American staff will review the Company periodically for compliance with the initiatives outlined in the Plan. If the Company is not in compliance with the continued listing standards by December 12, 2024, or if the Company does not make progress consistent with the Plan during the Plan period, NYSE American staff will initiate delisting proceedings as appropriate.

08:35 EDT Biomea Fusion appoints Juan Pablo Frias as CMO - Biomea Fusion announced the appointment of Juan Pablo Frias, M.D. as CMO. In his new role, Dr. Frias will leverage his deep industry and clinical investigator expertise in the development of therapeutics for the management of diabetes to oversee the clinical development of BMF-219, Biomea's novel investigational menin inhibitor, for the treatment of type 2 and type 1 diabetes. Steve Morris, M.D., will transition to the new role of Chief Development Officer, where he will continue to lead clinical development of Biomea's oncology portfolio, including BMF-219, BMF-500 and several early-stage oncology research candidates.Frias has held leadership positions in Clinical and Medical Affairs at Eli Lilly, Amylin Pharmaceuticals, Pfizer, and Johnson & Johnson, where he served as CMO and Global Vice President of Clinical and Medical Affairs, Diabetes Care.

08:34 EDT Femasys obtains MDEL from Health Canada - Femasys announced that it has obtained a Medical Device Establishment License, MDEL, from Health Canada. The MDEL license is issued by Health Canada's Regulatory Operations and Enforcement Branch, ROEB, to companies for the activities of manufacturing, importing and distributing and selling of medical devices for human use in Canada. This license allows Femasys to directly sell its four products, FemaSeed, FemVue, FemCath and FemCerv, approved in Canada. "Obtaining an MDEL license is another milestone achieved and key step to entering the Canadian marketplace," said Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys. "We are thrilled to provide women in Canada access to Femasys' medical products for infertility treatment and diagnosis, as well as cervical cancer diagnosis."

08:33 EDT GlucoTrack appoints Erin Carter to board of directors - Glucotrack has appointed Erin Carter to its Board of Directors and as Chair of its Audit Committee, effective immediately. From 2012 until March of 2023, she held various senior roles with Medtronic, most recently serving as Chief Financial Officer and Vice President of Finance for their $9B Neuroscience division.

08:31 EDT Eskay Mining drills VMS mineralization at four new projects - Eskay Mining announced it has recently drilled significant intervals of stockwork and/or massive sulfide mineralization at four new targets as part of its 2023 diamond drill campaign at its 100% controlled Consolidated Eskay Gold Project in the Golden Triangle of British Columbia. Precious metal-rich volcanogenic massive sulfide deposits are the focus of Eskay's exploration. As of this news release, Eskay Mining has drilled approximately 4,300m of its planned 6,500m 2023 diamond drill campaign. In Company news releases dated May 18 and July 27, 2023, seven new targets were discussed as subjects of this year's exploration campaign: Tarn Lake, Maroon Cliffs, Hexagon-Mercury, Storie Creek, Cumberland, Scarlet Knob-Bruce Glacier and TV South. Drilling at Tarn Lake, Scarlet Knob-Bruce Glacier, Hexagon-Mercury and Cumberland have yielded significant intercepts of stockwork and/or massive sulfide mineralization. Cumberland: This target is situated approximately five km south of the TV deposit, subject of substantial drilling over the past three seasons. No appreciable work has been conducted in this area for at least twenty years. A current total of five drill holes have been completed by Eskay Mining this season, each intercepting seafloor-proximal stockwork and massive sulfide mineralization over core lengths of approximately 25 to 85 meters. Spot XRF analyses indicates these intercepts are highly elevated in silver, copper, lead, zinc, arsenic, antimony and tellurium. Gold analysis by XRF is unreliable. This VMS deposit appears to strike NNW and dips moderately steeply to the east. Its stratigraphic position is believed to be in the Upper Hazelton Group at a level similar to the Eskay Creek deposit located approximately 20 km north. Like TV, Cumberland is situated on the eastern limb of the Eskay Anticline. The Company has one additional hole planned at Cumberland to follow up on this exciting new discovery. Scarlet Knob-Bruce Glacier: This target is situated along the eastern side of the toe of Bruce Glacier in an area where spot rock chip sampling returned several Au- and Ag-bearing assays, including one with 56 gpt Au last season. To date, four drill holes have probed the westward dipping succession of volcanic rocks in search of the paleo-sea floor exhalative position of the VMS system. All four holes have encountered significant intervals of 20-50m of intense stockwork mineralization followed by mudstone thought to represent the overlapping paleo-sea floor strata. Like Cumberland, spot XRF analyses indicates this stockwork mineralization is highly elevated in silver, copper, lead, zinc, arsenic, and antimony. Mineralization is believed to be hosted in the lower part of the Hazelton Formation. Further drilling will be conducted in an area approximately 200 m north of holes drilled to date near a newly discovered outcrop of base-metal-rich VMS mineralization. This exciting newly discovered massive sulfide mineralization is thought to be at or very close to the paleo-sea floor position. Tarn Lake: The Tarn-Lake target is situated on the west side of Bruce Glacier and saw limited drilling in 2022 that yielded encouraging precious metal results. Three holes completed to date have encountered sulfide stockwork mineralization ranging from 30-130m in length, much longer than recorded in drilling in 2022. Spot XRF analyses indicates this stockwork mineralization is highly elevated in silver, copper, lead, zinc, arsenic, and antimony. Mineralization is thought to be hosted by rocks in the lower part of the Hazelton Formation near a paleo-sea floor position much like Scarlet-Knob-Bruce Glacier to the east. One additional hole is being drilled at this exciting discovery this year. Hexagon-Mercury: Targeting at Hexagon-Mercury, situated on the western flank of the Eskay Anticline approximately 9 km south of Eskay Creek mine, has been driven by geophysical anomalies interpreted by Riaz Mirza of Simcoe Geoscience. The first of two drill holes completed to date yielded an intercept of over 100m of appreciable stockwork sulfide mineralization hosted by volcanic rock thought to be part of the lower Hazelton Group.Spot XRF analyses indicate this stockwork is moderately to strongly anomalous in arsenic and other pathfinder elements. Eskay Mining is contemplating following up this discovery with further drilling this season. The last target to be drill tested this season is Storie Creek, an as yet undrilled area situated just 3.5 km SSE of the Eskay Creek mine. Recent geologic interpretation by Eskay Mining's team discussed in a Company news release dated July 27, 2023 indicates that uppermost Hazelton Group strata including the Contact Mudstone sub-crops underneath the NE-trending Storie Creek drainage and dips gently northwestward underneath a veneer of post-mineral Bowser Lake Formation sedimentary rocks. Extensive gossanous outcrops of Upper Hazelton Formation rocks were discovered along the eastern side of Storie Creek over a strike length of at least 4 km. Gossan forms from weathering of sulfides that may be associated with mineralization. Upon review of historic soil data dating back to the early 1990's, Eskay's geologic team has identified two areas where high silver-in-soil values occur, an indication that the Storie Creek gossanous outcrops are likely associated with mineralization. Two drill holes are planned at Storie Creek beginning in a few days. One hole completed at TV South failed to encounter significant mineralization, however favorable volcanic host-rocks and VMS-related alteration were observed in drill core. Subsequent field discoveries of sulfide rich outcrops in areas nearby suggest this hole was drilled in an unfavorable orientation and that further exploration work is warranted at TV South. Two drill holes completed at the Maroon Cliffs target failed to encounter appreciable mineralization. Drilling at the Consolidated Eskay Project is expected to finish by mid-September. Assays from the first holes of the 2023 program are expected back late September.

08:25 EDT BriaCell accepts LOI from Weill Cornell Medicine on Bria-IMT trial plans - BriaCell Therapeutics has accepted a letter of intent from Dr. Massimo Cristofanilli, Director of Breast Medical Oncology and Associate Director of Precision Medicine in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, outlining the parties' plans and commitment, upon regulatory approval, to initiate a Phase 2 investigator-initiated clinical study to evaluate BriaCell's novel immunotherapy, Bria-IMT, in combination with a check point inhibitor, in early stage, newly diagnosed, high-risk triple negative breast cancer patients in the neoadjuvant setting. The clinical trial is designed to address the urgent and unmet need in high-risk TNBC patients who failed the current standard of care, a neoadjuvant regimen combination with check point inhibitors. The clinical trial is designed to evaluate the safety, and efficacy of the Bria-IMT combination regimen with CPI in early TNBC patients who completed neoadjuvant therapy and did not achieve pathological complete remission. The primary endpoint of event-free survival will be compared to the EFS of 55% in the historical control from Keynote 522.

08:15 EDT Academy Sports expects to open six stores in Q3 - During the second quarter, Academy opened one new store, bringing the total quarter-end number of stores to 270 stores. The Company expects to open six stores in the third quarter and five to six in the fourth quarter and a total of 120 to 140 stores over the five fiscal year period ending with fiscal 2027.

08:12 EDT 7GC & Co. announces initial filing of registration statement on Form S-4 - 7GC & Co. Holdings and Banzai International announced today that 7GC filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission on August 31, 2023. The Registration Statement contains a preliminary proxy statement and prospectus in connection with the previously announced proposed business combination, as amended between 7GC and Banzai. While the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides important information about 7GC and Banzai, as well as the proposed Business Combination. Upon closing of the proposed Business Combination, the combined company will be named Banzai International, Inc. and is expected to trade on the Nasdaq Capital Market.

08:11 EDT InspireMD announces abstract of 30-day results from C-Guardians U.S. IDE trial - InspireMD announced that an abstract detailing upcoming 30-day results from its C-Guardians U.S. Investigational Device Exemption, IDE, clinical trial has been accepted for presentation as a late-breaking clinical trial at the Vascular InterVentional Advances Annual Meeting, VIVA23, which is being held October 30 through November 2 in Las Vegas. Title: "30-Day Results from the C-Guardians Pivotal Trial of the CGuard Carotid Stent System." Marvin Slosman, chief executive officer of InspireMD, stated, "We are very pleased that an abstract detailing our 30-day follow-up data from our C-Guardians IDE trial has been accepted for presentation at this year's VIVA conference, which is among the most important gatherings of endovascular specialists each year. We believe CGuard(TM) EPS, with its novel MiroNet(TM) technology, offers next-level neuroprotection that translates into superior short- and long-term patient outcomes, something we aim to demonstrate with this important trial. We also look forward to sharing one-year data from C-Guardians in the second half of next year that, if positive, may support a Premarket Approval Application and allow us to potentially launch the CGuard Prime EPS stent system in the U.S. in the first half of 2025."

08:10 EDT Coya:Inflammation,oxidative stress may play role in severity/progression of ALS - Coya Therapeutics, reported the publication of a research article entitled "Immunological, Oxidative, and Structural Factors and Their Responses to Regulatory T Lymphocyte Therapy in Amyotrophic Lateral Sclerosis" in the peer-reviewed journal Ageing and Neurodegenerative Diseases. The publication reports the analyses of blood biomarker data from a cross sectional cohort of sporadic ALS patients and healthy controls and from two investigator-initiated clinical studies . In the IIT studies, patients were treated with expanded Treg cell therapy in combination with low-dose interleukin-2 . As previously reported, patients from these two trials experienced amelioration of disease progression with corresponding increased Treg numbers and suppressive function. Evidence strongly supports the role of inflammation and oxidative stress in the severity and rate of disease progression in ALS. These new biomarker data demonstrate that enhancing Treg function improves clinical outcomes with accompanying changes in blood levels of oxidative stress markers, such as 4-HNE, and inflammatory markers, including CCL2 and IL-18, and may have the potential to serve as objective biomarkers of disease progression and clinical trial endpoint surrogates to therapies that enhance Treg function. Following these encouraging results, Coya plans to assess blood markers of oxidative stress and inflammation systematically and prospectively in the upcoming well powered placebo controlled clinical study of COYA 302 in patients with ALS, aiming to provide a better understanding of the disease, with the ultimate goal of developing consistent biomarkers to evaluate treatment response.

08:08 EDT Peak Bio appoints Michael Friedman to board of directors - Peak Bio announce the appointment of one new independent board member, Michael Friedman, MBA as a Class III Director and as a member of the Company's Audit Committee and Compensation Committee. Mr. Friedman served as Senior Vice President at Ladenburg Thalmann & Co. Inc. Healthcare Investment Banking where he focused on M&A and capital markets from 2017 to 2023

08:07 EDT Maris-Tech receives new order from returning customer - Maris-Tech announced a new order from a repeat customer which provides video streaming solutions on advanced drone applications and is in a total amount of $120,000. "This new order from our customer serves as a testimony to our long-standing successful relationship and further establishes Maris-Tech's position as a technological company in the field of video recording and AI acceleration systems. This unique platform will facilitate critical AI-based applications in the defense market, and we anticipate a growing demand from the military for this solution," said Israel Bar, Chief Executive Officer of Maris-Tech.

08:06 EDT Gaming and Leisure Properties increases quarterly dividend to 73c per share - Gaming and Leisure Properties announced that, at its meeting yesterday, the Company's Board of Directors has declared the third quarter 2023 cash dividend of $0.73 per share of its common stock, an increase from the second quarter of $.01 per share per quarter. The dividend is payable on September 29, 2023 to shareholders of record on September 15, 2023. The third quarter 2022 cash dividend was $0.705 per share of the Company's common stock.

08:05 EDT Illumin announces final results of substantial issuer bid - illumin Holdings announced the final results of its substantial issuer bid, which expired at 5:00 p.m. on August 30, 2023. Under the Offer, the Corporation has purchased for cancellation 4,593,200 of its common shares at a purchase price of C$2.65 per Share, for an aggregate purchase price of approximately C$12,171,980. Shares purchased under the Offer represent approximately 8.18% of the issued and outstanding Shares at the time that the Offer was commenced. Immediately following the completion of the Offer and having taken into account the cancellation of the Shares purchased pursuant to the Offer, 51,592,431 Shares are now issued and outstanding. Canaccord Genuity Corp. and Canaccord Genuity LLC acted as dealer managers for the Offer and TSX Trust Company acted as the depositary for the Offer. Any questions regarding the Offer may be directed to the dealer managers or the Depositary. Payment for the Shares accepted for purchase under the Offer will occur in accordance with the terms of the Offer and applicable law.

08:04 EDT IBM and Salesforce partner to accelerate AI adoption - IBM (IBM) and Salesforce (CRM) announced a collaboration aimed to help businesses accelerate their adoption of AI for CRM. IBM Consulting and Salesforce are working with shared clients to accelerate business transformations with generative AI. IBM Consulting will guide clients through the adoption and deployment of Salesforce AI technologies. In addition to helping clients deploy Salesforce's generative AI tools, IBM Consulting can complement those solutions with IBM watsonx, an AI and data platform that embraces open standards. Through IBM Consulting Managed Services for Salesforce, shared clients will have access to a suite of AI experience and implementation accelerators.

08:02 EDT Karat Packaging announces COO Wang to retire, appoints Quire as CRO - Karat Packaging announced that its Chief Operating Officer, COO, Joanne Wang, will retire as an officer effective December 1, 2023. Wang also will relinquish her seat on the Company's five-person board, which will remain vacant until a successor is appointed. Karat also announced the appointment of Daniel Quire as Chief Revenue Officer, CRO, a newly created position. Quire most recently was the Company's Vice President of Sales, with more than a decade of sales management experience in the foodservice sector.

08:01 EDT NanoXplore's VoltaXplore enters supply agreement for Li-ion battery cells - NanoXplore and its wholly owned subsidiary, VoltaXplore announce that VoltaXplore has agreed on commercial terms for the supply of Li-ion battery cells with a well-known commercial vehicle OEM. Battery cells will be produced in VoltaXplore's gigafactory starting from 2026. The agreement is for 1 GWh per year for a duration of 10 years following a pricing formula that passes through raw material cost to the customer.

07:42 EDT Eightco announces Mobi-Hub Funding will be an exhibitor at IFA Berlin Show 2023 - Eightco announced that Mobi-Hub Funding, its joint venture between Eightco's wholly owned subsidiary, Forever 8 Fund and Mobi-Hub, is participating as an exhibitor at the renowned IFA Berlin Show 2023. This event provides an exclusive platform for Mobi-Hub Funding to spotlight its innovative solutions. During the IFA Berlin Show 2023, Mobi-Hub Funding hopes to strengthen strategic initiatives such as business expansion, general market awareness and enhancing knowledge about their distinctive service offerings, which encompass verified supply chain, financial resources, and more. "Participating in the IFA Berlin Show 2023 represents another milestone for Mobi-Hub Funding," noted Brian McFadden, CEO of Eightco. "Our plans to empower mobile resellers and marketplace operators with top-tier solutions, excellent funding options and supplier access underscores our dedication to reshaping the industry."

07:40 EDT Amedisys recognizes Suicide Prevention Awareness Month - Amedisys recognizes September as Suicide Prevention Awareness Month and joins the efforts to raise awareness for suicide prevention and mental health. In support of this important cause, Amedisys is highlighting the 988 Suicide and Crisis Lifeline which makes it easier for individuals in crisis to access crucial resources and assistance. The company said, "Recognizing the significance of this issue, Amedisys remains committed to providing compassionate care that supports the overall well-being of patients, families and communities. Amedisys has been providing behavioral health services for more than 10 years with our psychiatric skilled nurses to provide specialized at-home care for eligible patients with a mental health diagnosis."

07:38 EDT Vertical Aerospace's VX4 program moves to next phase - Vertical concluded its remote thrustborne flight test campaign in July 2023, as the first full-scale VX4 prototype reached its target speed of 40kts, demonstrating exceptional overall stability and control. Performance targets were generally exceeded by 10-30% during hover and low speed flights. The prototype performed especially well in sustained hover, typically the most challenging regime for a VTOL aircraft, where it maintained level flight for longer than anticipated. The aim of these thrustborne flight tests was to verify acceptable stability, battery efficiency and control characteristics, aerodynamics, structural loads, performance and vibration throughout this speed range - all of which were achieved. Incident Update: Vertical continued further uncrewed flight tests following the completion of the remote thrustborne flight test campaign. ...Vertical's investigation identified the root cause to be a fault with a propeller. This early generation propeller had already been redesigned prior to the incident, with the issue fully resolved ahead of the next phase of testing. Further recommendations by the investigation are being implemented by Vertical. Vertical believes transparency and openness is fundamental to the safety of aerospace. It therefore intends to provide a further full update to the industry on the incident once the AAIB's investigation has concluded...This demonstrator is expected to be ready to fly early next year. Its components will include technology from most of Vertical's certification partners: Honeywell, GKN Aerospace, Hanwha, Solvay, Leonardo and Molicel. An additional, identical full-scale aircraft has also now been approved and is expected to be flying in the second half of 2024.

07:35 EDT Scotiabank announces senior leadership appointments - Scotiabank's Group Head and Chief Human Resources Officer Barb Mason has announced her intention to retire from Scotiabank at the end of 2023, after a 41-year career with the bank. Scotiabank has appointed Jenny Poulos as Deputy CHRO, effective October 2, and will assume the role of CHRO on December 4. Poulos has more than 34 years of experience at another large Canadian financial institution, where she was most recently SVP, Talent Services, and has assumed progressively senior roles in Retail and HR. Scotiabank also appointed Aris Bogdaneris to the newly created role of Group Head, Digital Transformation, Tangerine, Marketing and Analytics, effective September 1. Bogdaneris will be responsible for overseeing the Tangerine business as well as Global Marketing, Customer Insights, Data and Analytics and Real Estate. Bogdaneris most recently served at an international bank, as the Global Head of Retail Banking and Head of Challenger and Growth Markets. Scotiabank also announced additional changes to its Senior Leadership Team: Phil Thomas has been promoted to Group Head and Chief Risk Officer. Paul Baroni has been appointed EVP, Finance and CFO, Canadian Banking. Baroni has been with the Bank for more than 22 years, in roles across Audit, Finance and Operations. Maria Theofilaktidis has been appointed EVP and Chief Auditor. Theofilaktidis has been with the Bank for more than 21 years as part of the Global Finance leadership team. Anique Asher, EVP, Finance and Strategy, will assume an expanded mandate that includes oversight of Capital Management. Asher joined Scotiabank in 2018 as part of the Global Finance leadership team. Chris Manning has been appointed EVP, Global Business Payments. Manning has been with the Bank for more than 15 years in progressively senior roles in Business Banking, International Banking, Risk, and most recently, leading the Global Business Payments business since 2020.

07:27 EDT Duluth Holdings CFO Dave Loretta stepping down - Duluth Holdings CFO Dave Loretta has decided to step down on September 15 to accept an employment opportunity outside the company. A formal search process for the selection of a new CFO has been initiated by the company. Until that process is completed, Michael Murphy, VP, Chief Accounting Officer will also serve as Interim CFO, effective September 15. Murphy has been in his current position since 2019. Prior to joining the company, Murphy served for 3 years as Chief Accounting Officer at First Business Financial Services. Murphy's employment experience also includes 8 years at KPMG, LLP in several capacities.

07:14 EDT Orchard Therapeutics announces long-term results from analysis of OTL-200 - Orchard Therapeutics announced long-term results from an updated integrated analysis of 39 patients with metachromatic leukodystrophy treated with investigational OTL-200 in the clinical development program. The data were presented yesterday at the ongoing Society for the Study of Inborn Errors of Metabolism Annual Symposium in Jerusalem. Thirty-nine pediatric patients with early-onset MLD, enrolled in two prospective non-randomized clinical studies or treated under expanded access frameworks were administered OTL-200 and compared with natural history data from 49 untreated patients. All treated patients were administered OTL-200 and subsequently monitored at Ospedale San Raffaele in Milan, Italy. The composite endpoint used in the updated integrated analysis is severe motor impairment-free survival, defined as the interval from birth to the first occurrence of loss of locomotion and loss of sitting without support or death. Importantly, use of sMFS was discussed with the U.S. Food and Drug Administration who agreed it is clinically meaningful. At the time of the updated integrated analysis, results from treated patients showed: Efficacy: Treatment with OTL-200 resulted in statistically significant and clinically meaningful improvement in sMFS in the pre-symptomatic late infantile, pre-symptomatic early juvenile and early-symptomatic early juvenile MLD subgroups compared to disease natural history. Seventeen of 18 pre-symptomatic late infantile patients maintained the ability to walk at last assessment, in contrast to untreated late infantile natural history patients, all of whom lost all locomotion by a median age of 2.6 years. All seven surviving pre-symptomatic early juvenile patients maintained the ability to walk without support with quality and performance normal for age at last assessment, and seven of nine surviving early-symptomatic early juvenile patients maintained the ability to sit without support and/or crawl/roll at last assessments, in contrast with untreated early juvenile natural history patients, all of whom lost all locomotion by a median age of 6.4 years. Seventeen of 18 pre-symptomatic late infantile, all seven surviving pre-symptomatic early juvenile, and six of nine surviving early-symptomatic early juvenile patients have continued to acquire cognitive skills as expected for age, shown by the upward trajectory of performance and verbal age-equivalents over chronological ages. All treated patients had reconstituted ARSA activity in peripheral blood mononuclear cells with geometric mean values within or above normal range by three months post-treatment and in cerebrospinal fluid by three to six months post-treatment, which has been sustained throughout follow-up. Safety: With more than a cumulative 250 patient-years of follow-up, treatment with OTL-200 was generally well-tolerated, with no treatment-related serious adverse events or deaths. Most adverse events were associated with busulfan conditioning or background disease. There were three patient deaths observed in the study, none of which were considered related to treatment with OTL-200. Six treatment-related adverse events of anti-ARSA antibodies reported, which resolved either spontaneously or after B-cell depleting therapy with no impact on clinical outcome. Antibody titers in all cases were generally low and no negative effects were observed in the engraftment of gene-corrected cells or in post-treatment ARSA activity. Delayed platelet engraftment occurred in four patients all of which resolved within the first four months after conditioning with no bleeding events reported. One patient with a complex medical history and comorbidities experienced prolonged anemia and thrombocytopenia requiring infusion of unmanipulated back-up cells and remains in good clinical condition. There have been no cases of malignancy or insertional oncogenesis and no evidence of clonal dominance or expansion reported to date, consistent with other Orchard lentiviral HSC gene therapy studies.

07:10 EDT Codere Online sees 2023 net gaming revenue EUR 150M - EUR 160M - Oscar Iglesias, CFO of Codere Online, stated, "We continue delivering strong revenue growth, despite a lower level of marketing investment, on the back of strong brand recognition, higher quality customers and continued improvement in our product offering. This has allowed us to reduce our Adjusted EBITDA loss by more than half to negative EUR 4.5 million in the second quarter. We feel very encouraged by first half results, which continue to exceed our original expectations, and now expect to generate between EUR 150-160 million of net gaming revenue in 2023, a 7% increase at the midpoint versus our prior outlook. In regards to Adjusted EBITDA, we expect to deliver negative EUR 15-25 million, and believe we are well on track to deliver positive EBITDA and cash flow for the full year in 2024."

07:06 EDT Spire Global awarded $4.6M NASA contract - Spire Global announced it was awarded a $4.6M, 12-month contract by NASA on behalf of the National Oceanic and Atmospheric Administration, or NOAA, to participate in NOAA's Sounder for Microwave-Based Applications, or SMBA, Phase-A study. During this phase, Spire will compete with three other companies to develop a Microwave Sounder for NOAA's Near-Earth Orbit Network, or NEON, program. Following the completion of the 12-month contract, a single sounder from the finalists may be selected for additional contract phases that may lead to integration into NOAA's NEON program series of Low-Earth orbit, or LEO, satellites, with the initial launch scheduled for no earlier than 2030. The data collected from the final Microwave Sounder will be used towards advancing Earth observation, providing insights into various atmospheric properties such as temperature, humidity, cloud cover and composition.

07:05 EDT Dollar General says FY23 guidance continues to assume no share repurchases

07:03 EDT CytoSorbents granted expanded ANVISA registration to treat shock with CytoSorb - CytoSorbents announced that CytoSorb was granted an expanded medical device registration by the Brazilian Health Regulatory Agency, ANVISA, to treat shock. After receiving its first ANVISA registration in September 2020 to treat cytokine storm in cardiac surgery and critical illnesses such as COVID-19 in the midst of the COVID pandemic, CytoSorb has now received an expanded ANVISA registration to also include the treatment of shock - a common and frequently fatal complication of critical illness and cardiac surgery.

06:59 EDT Dollar General backs FY23 CapEx $1.6B-$1.7B - Backs FY23: 3,110 real estate projects in the United States, including 990 new store openings, 2,000 remodels, and 120 store relocations.

06:55 EDT Visa announces volume and transaction data for July and to August 28 - Visa announced volume and transaction data for July and from August 1-28. "As previously disclosed, in March 2022, we suspended our operations in Russia and therefore Russia-related volume and transaction data are not included in our results from April 2022 through August 2023. August U.S. payments volume on a year-over-year basis grew 7%. Credit grew 6% and Debit grew 7%. August card not present volume on a year-over-year basis was up 9%, card not present volume excluding travel was up 9% and card present volume was up 4%. August payments volume year-over-year growth for key international markets improved slightly relative to July 2023 year-over-year growth. August cross-border volume excluding intra-Europe transactions was 151% of 2019, with card not present volume excluding travel at 172% of 2019. Total card present and card not present travel cross-border volume excluding intra-Europe transactions was 141% of 2019. August travel cross-border volume into and from our Asia Pacific region and into the U.S. continued to improve relative to 2019 levels. August global processed transactions grew 10% year-over-year," the company stated in a regulatory filing last night.

06:39 EDT Celsius Holdings and US Bitcoin Corp sign deal for 8,500 miners - Celsius Holdings (CELH) has secured a deal with U.S. Data Mining Group, dba US Bitcoin Corp, an operator of large-scale data centers for new-age workloads such as digital asset mining, to host an initial 8,500 miners with an estimated sticker hashrate of 820 PH at the USBTC Alpha Site. This agreement continues the collaboration between USBTC and Celsius, with support from the Fahrenheit coalition which includes USBTC, Arrington Capital, Proof Group Capital Management, Steven Kokinos, and Ravi Kaza. In aggregate, USBTC anticipates managing a fleet of more than 310,000 bitcoin miners including miners owned by Celsius, other clients, and its own machines. The parties are working diligently to complete the implementation of the deal and begin operations as soon as possible. In aggregate, USBTC expects to manage a fleet of more than 310,000 bitcoin miners across Celsius and hosted assets. On February 7, the company announced an all-stock merger of equals with Hut 8 Mining (HUT). The combined company will be named "Hut 8 Corp." and will be a U.S.-domiciled entity.

06:33 EDT Sage Therapeutics announces plans to reorganize business operations - Sage Therapeutics announced plans to reorganize its business operations and pipeline priorities to support goals for long-term business growth, including the planned commercial launch of ZURZUVAE for women with postpartum depression in late 2023. Following a strategic review, the company will: Refine pipeline development efforts to advance SAGE-718 and SAGE-324, as well as pause certain earlier-stage programs, with the goal of making evidence-driven investments; Implement a ~40% workforce reduction designed to right-size the organization as the company works to achieve sustained growth and allow for commercial hires to support the goal of a successful launch of ZURZUVAE to treat women with PPD; Align its leadership team structure to scale with pipeline and commercial priorities. The reorganization plan is intended to enable Sage to strengthen its balance sheet and position the company for long-term growth potential. Based on the post-reorganization operating plan which includes Sage's pipeline prioritization, workforce reduction, and additional incremental commercial hires, the company expects: Annualized net savings of approximately $240 million, of which 60% is related to R&D; A non-recurring charge of approximately $36 million to $38 million associated with the reorganization, primarily incurred in the third quarter of 2023; The potential to earn a milestone payment of $75 million from Biogen related to the first commercial sale of ZURZUVAE for the treatment of PPD; Cash, cash equivalents, and marketable securities of approximately $1.0 billion as of June 30, 2023 along with anticipated funding from ongoing collaborations and potential revenue will support operations into 2026.

06:14 EDT KE Holdings upsizes, extends share repurchase program - KE Holdings announced that its board of directors has approved the upsizing and extension of its share repurchase program and the declaration of a special cash dividend. As previously disclosed, in August 2022, the company established a share repurchase program under which the Company may purchase up to $1B of its Class A ordinary shares and/or ADSs over a 12-month period. From the launch of the share repurchase program in September 2022 to August 2023, the company in aggregate purchased approximately 41M American depositary shares in the open market at a total consideration of approximately $605M pursuant to the share repurchase program. On August 31, 2023, the company's board of directors approved modifications to the existing share repurchase program, pursuant to which the repurchase authorization has been increased from $1B of its Class A ordinary shares and/or ADSs to $2B of its Class A ordinary shares and/or ADSs and extended until August 31, 2024. In the annual general meeting held on June 15, 2023, the shareholders of the company have approved to grant the board of directors a general unconditional mandate to purchase the company's own shares which covers the repurchases under the Extended Share Repurchase Program until the conclusion of the next AGM of the company. After the expiry of the 2023 Share Repurchase Mandate, the company will seek for another general unconditional mandate for repurchase from the shareholders of the company at the next AGM to continue its share repurchase under the Extended Share Repurchase Program.

06:05 EDT Microsoft to unbundle Teams from Microsoft 365, Office 365 suites - Last month, the European Commission announced that it had opened a formal investigation regarding Microsoft's bundling of Microsoft Teams with Microsoft 365 and Office 365 suites for business customers. Today Microsoft is announcing proactive changes that "we hope will start to address these concerns in a meaningful way, even while the European Commission's investigation continues and we cooperate with it," the company said. These changes will impact Microsoft 365 and Office 365 suites for business customers in the European Economic Area and Switzerland. The changes are designed to address two concerns that are central to the Commission's investigation: (1) that customers should be able to choose a business suite without Teams at a price less than those with Teams included; and (2) that the company should do more to make interoperability easier between rival communication and collaboration solutions and Microsoft 365 and Office 365 suites. First, beginning October 1, 2023, Microsoft will unbundle Teams from Microsoft 365 and Office 365 suites in the EEA and Switzerland. Microsoft will instead sell these offerings without Teams at a lower price, EUR 2 less per month or EUR 24 per year. Teams will still be available for new enterprise customers to buy standalone and separately at a list price of EUR 5 per month or EUR 60 per year. Second, Microsoft will enhance its existing resources on interoperability with Microsoft 365 and Office 365. Finally, Microsoft will create new mechanisms to enable third-party solutions to host Office web applications. Reference Link

05:25 EDT Twist Bioscience enters drug discovery agreement with Ono Pharmaceutical - Twist Bioscience announced a drug discovery agreement with Ono Pharmaceutical Co. to discover and develop novel antibodies for the treatment of autoimmune diseases. Under the terms of the agreement, Twist will utilize the Twist Biopharma Solutions Library of Libraries to conduct research activities to discover novel antibodies against targets identified by Ono. Twist's Library of Libraries is an expansive collection of synthesized antibody libraries based on naturally occurring sequences that harness innovative structural and developability features to cover a wide range of drug targets. Twist will receive research fees, success-based clinical and regulatory milestones, as well as royalties on product sales. As part of the strategic collaboration, Ono will also utilize the scientific expertise of the Biopharma Solutions team and Twist's Premium Project Management services to evaluate new targets and generate comprehensive discovery campaigns. Ono will be responsible for the development, manufacturing and commercialization of any products resulting from the collaboration.